Impact of MDM2 polymorphism: Increased risk of developing colorectal cancer and a poor prognosis in the Tunisian population

European Journal of Gastroenterology and Hepatology

Volumn 24, Issue 3, 2012, Pages 320-327

  Chaar, Ines ^a   Arfaoui, Toumi Amira ^a   El Amine, El Hadj Olfa ^a,b   Mahmoud, Lilia Ben ^a   Khiari, Mariem ^a   Sammoud, Soraya ^a   Lounis, Amine ^a   Amara, Semeh ^a   Gharbi, Lassad ^a,c   Hmida, Abdelmajid Ben ^a,d   Mzabi, Sabeh ^b   Bouraoui, Saadia ^a,b  

^a UNIVERSITY OF TUNIS   (Tunisia)

^b Departments of Pathology and Cytology   (Tunisia)

^c MONGI SLIM HOSPITAL   (Tunisia)

^d UNIVERSITY OF TUNIS EL MANAR   (Tunisia)

Author keywords

Colorectal cancer; immunohistochemistry; MDM2; p53; polymerase chain reaction; SNP 309

Indexed keywords

PROTEIN MDM2;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; TUNISIA;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INTESTINAL MUCOSA; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MDM2; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 84856714151     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32834bdf84     Document Type: Article

References (50)

1. Klein C, Vassilev LT. Targeting the p53-MDM2 interaction to treat cancer. Br J Cancer 2004; 91:1415-1419. (Pubitemid 39486340)
2. Chaoliang X, Jun L, Lingxian Y, Yuan H. Methylation of p14ARF and abnormal expression of p53 and MDM2 in colorectal cancer: role and correlation. Sci Res Essays 2010; 5:1669-1675.
3. Deepak R, Rehan A, Ch Dongshu, Shailendra K, Surender K, Donald K. MUC1 oncoprotein suppresses activation of the ARF-MDM2-P53 pathways. Cancer Biol Ther 2008; 7:1959-1967.
4. Hao X, Gunther T, Roessner A, Price AB, Talbott IC. Expression of MDM2 and p53 in epithelial neoplasms of the colo- rectum. Mol Pathol 1998; 51:26-29. (Pubitemid 28157353)
5. Momand J, Jung D, Wilczynski S, Niland J. The MDM2 gene amplification database. Nucleic Acids Res 1998; 26:3453-3459. (Pubitemid 28347214)
6. Fakharzadeh SS, Trusko SP, George DL. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J 1991; 10:1565-1569. (Pubitemid 21905621)
7. Jones SN, Hancock AR, Vogel H, Donehower LA, Bradley A. Overexpression of MDM2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc Natl Acad Sci USA 1998; 95:15608-15612. (Pubitemid 29018747)
8. Momand J, Wu HH, Dasgupta G. MDM2-master regulator of the p53 tumor suppressor protein. Gene 2000; 242:15-29. (Pubitemid 30064488)
9. Freedman DA, Wu L, Levine AJ. Functions of the MDM2 oncoprotein. Cell Mol Life Sci 1999; 55:96-107. (Pubitemid 29077858)
10. Juven-Gershon T, Oren M. MDM2: the ups and downs. Mol Med 1999; 5:71-83. (Pubitemid 29230686)
11. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressorpathwayand accelerates tumor formation in humans. Cell 2004; 119:591-602. (Pubitemid 39535748)
12. Bond GL, Hu W, Levine A. A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Cancer Res 2005; 65:5481-5484. (Pubitemid 40911143)
13. Ries S, Biederer C, Woods D, Shifman O, Shirasawa S, Sasazuki T, et al. Opposing effects of Ras on p53: transcriptional activation of MDM2 and induction of p19ARF. Cell 2000; 103:321-330.
14. Zauberman A,Flusberg D, Haupt Y, Barak Y, Oren M.Afunctionalp53- responsive intronic promoter is contained within the human MDM2 gene. Nucleic Acids Res 1995; 23:2584-2592.
15. Lind H, Zienolddiny S, Ekstrom PO, Skauq V, Haugen A. Association of a functional polymorphism in the promoter of the MDM2 gene with risk of non small cell lung cancer. Int JCancer 2006; 119:718-721. (Pubitemid 43955729)
16. Hong Y, Miao X, Zhang X, Ding F, Luo A, Guo Y, et al. The role of P53 and MDM2 polymorphisms in the riskof esophageal squamous cell carcinoma. Cancer Res 2005; 65:9582-9587. (Pubitemid 41508029)
17. Ohmiya N, Taguchi A, Mabuchi N, Itoh A, Hirooka Y, Niwa Y, et al. MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J Clin Oncol 2006; 20: 4434-4440. (Pubitemid 46630981)
18. Menin C, Scaini MC, De Salvo GL, Biscuola M, Quaggio M, Esposito G, et al. Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. Bertorelle Journal of the National Cancer Institute 2006;285-288. (Pubitemid 43264712)
19. Merup M, Juliusson G, Xu XH, Jassun M, Ste Uan B, Rasool O, et al. Amplification of multiple regions of chromosome 12, including 12q13-15, in chronic lymphocytic leukemia. Eur J Hematol 1997; 58:174-180. (Pubitemid 27183467)
20. Nakayama T, Tognchida J, Wadayama B, Kanoe H, Kotoura Y, Sasaki M. MDM2 gene amplification in bone and soft- tissue tumors: association with tumor progression in differ- entiated adipose-tissue tumors. Int J Cancer 1995; 64:342-346.
21. Nilbert M, Rydholm A, Millen H, Mitelman F, Mandahl N. MDM2 gene amplification correlates with ring chromosomes in soft tissue tumors. Genes Chromosomes Cancer 1994; 9:261-267.
22. Giannikaki E, Kouvidou C,Tzardi M, Stefanaki K, Koutsoubi K, Gregoriou M, et al. p53 protein expression in breast carcinoma. Cooperative study with wild type p53 induced proteins MDM2 and p21/WAF1. Anticancer Res 1997; 17:2123-2127. (Pubitemid 27320956)
23. Ghada AF, Boris Y, Bhuvaneswari K, Vladimir K, Kamal L. MDM2/p53 protein expression in the development of colorectal adenocarcinoma. J Gastrointest Surg 2000; 4:109-114.
24. Ogata M, Naito Z, Tanaka S, Moriyama Y, Asana G. Overexpression and localization of heat shock proteins m RNA in pancreatic carcinoma. J Nippon Med Sch 2000; 67:1 77-185.
25. Leopoldo S, Lorena B, Cinzia A, Gabriella DC, Angela Luciana B, Renato C, et al. Two subtypes of mucinous adenocarcinoma of the colorectum: clinicopathological and genetic features. Ann Surg Oncol 2008; 15: 1429-1439.
26. Li D, Semba S,Wu M,Yokozaki H. Molecular pathological sub classification of mucinous adenocarcinoma of the colorectum. Pathol Int 2005; 55:766-774. (Pubitemid 43110202)
27. Song GA, Deng G, Bell I, Kakar S, Sleisenger MH, Kim YS. Mucinous carcinomas of the colorectum have distinct molecular genetic characteristics. Int J Oncol 2005; 26:745-750.
28. Adell R, Marcote E, Segarra MA, Pellicer V, Gamón R, Bayón AM, et al. Is mucinous colorectal adenocarcinoma a distinct entity? Gastroenterol Hepatol 2002; 25:534-540. (Pubitemid 36336754)
29. Kondo I, Lida S,Takagi Y, Sugihara K. MDM2 m RNA expression in the p53 pathway may predict the potential of invasion and liver metastasis in colorectal cancer. Dis Colon Rectum 2008; 51:1395-02.
30. Millon R, Muller D, Schultz I, Salvi R, Ghnassia JP, Frebourg T, et al. Loss of MDM2 expression in human head and necksquamous cell carcinomas and clinical significance. Oral Oncol 2001; 37:620-631. (Pubitemid 32925196)
31. Wurl P,Meye A,Schmidt H,Lautenschläger C, Kalthoff H, Rath FW,et al. High prognostic significance of Mdm2/p53 co-overexpression in soft tissue sarcomas of the extremities. Oncogene 1998; 16:1183-1185. (Pubitemid 28127517)
32. Schiebe M, Ohneseit P, Hoffmann W, Meyemann R, Rodemann HP, Bamberg M. Analysis of MDM2 and p53 gene alterations in glioblastomas and its correlation with clinical factors. J Neurooncol 2000; 49:197-203. (Pubitemid 32106781)
33. Gustafsson B, Axelsson B, Gustafsson B, Christensson B, Winiarski J. MDM2 and p53 in childhood acute lymphoblastic leukemia: higher expression in childhood leukemias with poor prognosis compared to long-term survivors. Pediatr Hematol Oncol 2001; 18:497-508. (Pubitemid 33108272)
34. Lukas J,Gao DQ,Kashmeshian M,Wen WH,Tsao-Wei D,Rosenberg S, et al. Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer. Cancer Res 2001; 61:3212-3219. (Pubitemid 32691978)
35. Hori M, Shimazaki J, Inagawa S, Itabashi M, Hori M. Overexpression of MDM2 oncoprotein correlates with possession of estrogen receptor alpha and lack of MDM2 m RNA splice variants in human breast cancer. Breast Cancer Res Treat 2002; 71:77-83.
36. Higashiyama M,Doi O, Kodama K,Yokouchi H,Kasugai T, Ishiguro S,et al. MDM2 gene amplification and expression in non-small-cell lung cancer: immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation. Br J Cancer 1997; 75:8.
37. Polsky D, Bastian BC, Hazan C, Melzer K, Pack J, Houghton A, et al. HDM2 protein overexpression, but not gene amplification, is related to tumorogenesis of cutaneous melanoma. Cancer Res 2001; 61:7642-7646. (Pubitemid 32995060)
38. Polsky D,Melzer K, Hazan C, Panageas KS, Busam K,Drobnjak M,et al. HDM2 protein overexpression and prognosis in primary malignant melanoma. J Natl Cancer Inst 2002; 94:1803-1806. (Pubitemid 36004356)
39. Harris SL, Gil G,Robins H,Hu W, Hirshfield K,Bond E,et al. Detection of functional single-nucleotide polymorphisms that affect apoptosis. Proc Natl Acad Sci USA 2005; 102:16297-16302. (Pubitemid 41688908)
40. Houlston RS, Peto J. The future of association studies of common cancers. Hum Genet 2003; 112:434-435. (Pubitemid 36869075)
41. Bond GL, Levine AJ. A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to infiuence cancer in humans. Oncogene 2007; 26:1317-1323. (Pubitemid 46328460)
42. Ray RM, Bhattacharya S, Johnson LR. MDM2 inhibition induces apoptosis in p53 deficient human colon cancer cells by activating p73- and E2F1-mediated expression of PUMA and Siva-1. Apoptosis 2011; 16:35-44.
43. Arva NC,Gopen TR,Talbott KE,Campbell LE,Chicas A,White DE,et al A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in MDM2 SNP309 homozygous cells. J Biol Chem 2005, 280, 26776-26787. (Pubitemid 41040711)
44. Ttigashyama M, Doi O, Ykokouchi H, Kasugal T, Ishiguro S, Takami K, et al. MDM2 gene amplification and expression in non-small cell lung cancer: immunohistochemical expression of its protein is a favorable prognostic marker in patients without p53 accumulation. Br J Cancer 1997; 75: 1302-1308. (Pubitemid 27179820)
45. Drager BJ, Kushima M, Goebell P, Jax TW, Gerharz CD, Bultel H, et al. P53 and MDM2 in the development and progression of bladder cancer. Eur Urol 1997; 32:487-493. (Pubitemid 27501052)
46. Barnes DM, Hanby AM, Gillett CE, Mohanled S, Hogson S, Bobrow LG, et al. Abnormal expression of wild type p53 protein in normal cells of cancer family patient. Lancet 1992; 340:259-263.
47. Grimm M-O, Jurgens B, Schulz WA, Makri D, Schmitz Drager BJ. Inactivation of tumor suppressor genes and deregulation of the c-myc gene in urothelial cancer cell lines. Urol Res 1995; 23:293-300.
48. Haupt Y, Maya R, Kazaz A, Oren M. MDM2 promotes rapid degradation of p53. Nature 1997; 387:296-299. (Pubitemid 27220766)
49. Wilkening S, Bermejo JL, Hemminki K. MDM2 SNP309 and cancer risk: a combined analysis.. Carcinogenesis 2007; 28:2262-2267. (Pubitemid 350119563)
50. Antoniou AC, Easton DF. Polygenic inheritance of breast cancer: implications for design of association studies. Genet Epidemiol 2003; 25:190-202. (Pubitemid 37296594)